NF-κB in cancer - A friend turned foe

Research output: Contribution to journalArticle

Abstract

The nuclear factor of κB (NF-κB) family of heterodimeric transcription factors plays an instrumental role in immune, inflammatory, and stress responses. NF-κB induces the expression of diverse target genes that promote cell cycle progression, regulate apoptosis, and facilitate cell adhesion, angiogenesis, and metastasis. Given the ability of NF-κB to influence these cardinal features of neoplastic transformation, it is no surprise that tumor cells of almost every tissue type acquire the ability to constitutively activate NF-κB via a host of diverse genetic alterations and viral proteins. The activation of NF-κB not only enables malignant transformation and tumor progression, but also provides a mechanism by which tumor cells escape immune surveillance and resist therapy. NF-κB may be inhibited by targeting either the apical signaling proteins responsible for its activation in specific types of cancer, the downstream kinases (IκB kinase and casein kinase 2) at which NF-κB-activating signaling pathways converge, the proteasome-mediated degradation of the inhibitor of κB (IκB) proteins, or the transcriptional activity of Re1 proteins. Since NF-κB inhibitors can sensitize tumor cells to apoptosis signaling pathways activated by death receptors, interferons, and immune effector cells, they hold enormous promise for the development of effective combinatorial regimens against a wide spectrum of hematologic and epithelial malignancies.

Original languageEnglish (US)
Pages (from-to)53-67
Number of pages15
JournalDrug Resistance Updates
Volume7
Issue number1
DOIs
StatePublished - Feb 2004

Fingerprint

Neoplasms
Phosphotransferases
Apoptosis
Tumor Escape
Casein Kinase II
cdc Genes
Death Domain Receptors
Viral Proteins
Hematologic Neoplasms
Proteasome Endopeptidase Complex
Cell Adhesion
Interferon-gamma
Proteins
Transcription Factors
Neoplasm Metastasis
Therapeutics
IgA receptor

Keywords

  • Apoptosis
  • Cancer
  • Carcinogenesis
  • CK2
  • IKK
  • NF-‰B
  • Treatment

ASJC Scopus subject areas

  • Cancer Research
  • Infectious Diseases
  • Oncology
  • Pharmaceutical Science

Cite this

NF-κB in cancer - A friend turned foe. / Ravi, Rajani; Bedi, Atul.

In: Drug Resistance Updates, Vol. 7, No. 1, 02.2004, p. 53-67.

Research output: Contribution to journalArticle

@article{9a18f6f6ba8042d8b973fae65d6300f1,
title = "NF-κB in cancer - A friend turned foe",
abstract = "The nuclear factor of κB (NF-κB) family of heterodimeric transcription factors plays an instrumental role in immune, inflammatory, and stress responses. NF-κB induces the expression of diverse target genes that promote cell cycle progression, regulate apoptosis, and facilitate cell adhesion, angiogenesis, and metastasis. Given the ability of NF-κB to influence these cardinal features of neoplastic transformation, it is no surprise that tumor cells of almost every tissue type acquire the ability to constitutively activate NF-κB via a host of diverse genetic alterations and viral proteins. The activation of NF-κB not only enables malignant transformation and tumor progression, but also provides a mechanism by which tumor cells escape immune surveillance and resist therapy. NF-κB may be inhibited by targeting either the apical signaling proteins responsible for its activation in specific types of cancer, the downstream kinases (IκB kinase and casein kinase 2) at which NF-κB-activating signaling pathways converge, the proteasome-mediated degradation of the inhibitor of κB (IκB) proteins, or the transcriptional activity of Re1 proteins. Since NF-κB inhibitors can sensitize tumor cells to apoptosis signaling pathways activated by death receptors, interferons, and immune effector cells, they hold enormous promise for the development of effective combinatorial regimens against a wide spectrum of hematologic and epithelial malignancies.",
keywords = "Apoptosis, Cancer, Carcinogenesis, CK2, IKK, NF-‰B, Treatment",
author = "Rajani Ravi and Atul Bedi",
year = "2004",
month = "2",
doi = "10.1016/j.drup.2004.01.003",
language = "English (US)",
volume = "7",
pages = "53--67",
journal = "Drug Resistance Updates",
issn = "1368-7646",
publisher = "Churchill Livingstone",
number = "1",

}

TY - JOUR

T1 - NF-κB in cancer - A friend turned foe

AU - Ravi, Rajani

AU - Bedi, Atul

PY - 2004/2

Y1 - 2004/2

N2 - The nuclear factor of κB (NF-κB) family of heterodimeric transcription factors plays an instrumental role in immune, inflammatory, and stress responses. NF-κB induces the expression of diverse target genes that promote cell cycle progression, regulate apoptosis, and facilitate cell adhesion, angiogenesis, and metastasis. Given the ability of NF-κB to influence these cardinal features of neoplastic transformation, it is no surprise that tumor cells of almost every tissue type acquire the ability to constitutively activate NF-κB via a host of diverse genetic alterations and viral proteins. The activation of NF-κB not only enables malignant transformation and tumor progression, but also provides a mechanism by which tumor cells escape immune surveillance and resist therapy. NF-κB may be inhibited by targeting either the apical signaling proteins responsible for its activation in specific types of cancer, the downstream kinases (IκB kinase and casein kinase 2) at which NF-κB-activating signaling pathways converge, the proteasome-mediated degradation of the inhibitor of κB (IκB) proteins, or the transcriptional activity of Re1 proteins. Since NF-κB inhibitors can sensitize tumor cells to apoptosis signaling pathways activated by death receptors, interferons, and immune effector cells, they hold enormous promise for the development of effective combinatorial regimens against a wide spectrum of hematologic and epithelial malignancies.

AB - The nuclear factor of κB (NF-κB) family of heterodimeric transcription factors plays an instrumental role in immune, inflammatory, and stress responses. NF-κB induces the expression of diverse target genes that promote cell cycle progression, regulate apoptosis, and facilitate cell adhesion, angiogenesis, and metastasis. Given the ability of NF-κB to influence these cardinal features of neoplastic transformation, it is no surprise that tumor cells of almost every tissue type acquire the ability to constitutively activate NF-κB via a host of diverse genetic alterations and viral proteins. The activation of NF-κB not only enables malignant transformation and tumor progression, but also provides a mechanism by which tumor cells escape immune surveillance and resist therapy. NF-κB may be inhibited by targeting either the apical signaling proteins responsible for its activation in specific types of cancer, the downstream kinases (IκB kinase and casein kinase 2) at which NF-κB-activating signaling pathways converge, the proteasome-mediated degradation of the inhibitor of κB (IκB) proteins, or the transcriptional activity of Re1 proteins. Since NF-κB inhibitors can sensitize tumor cells to apoptosis signaling pathways activated by death receptors, interferons, and immune effector cells, they hold enormous promise for the development of effective combinatorial regimens against a wide spectrum of hematologic and epithelial malignancies.

KW - Apoptosis

KW - Cancer

KW - Carcinogenesis

KW - CK2

KW - IKK

KW - NF-‰B

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=1842607516&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1842607516&partnerID=8YFLogxK

U2 - 10.1016/j.drup.2004.01.003

DO - 10.1016/j.drup.2004.01.003

M3 - Article

C2 - 15072771

AN - SCOPUS:1842607516

VL - 7

SP - 53

EP - 67

JO - Drug Resistance Updates

JF - Drug Resistance Updates

SN - 1368-7646

IS - 1

ER -